Notify me when Clearline Capital LP files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| HRTX | HERON THERAPEUTICS, INC. /DE/ | Common Stock, par value $0.01 per share | 6.7% | $18,108,154 | +$3,733,614 | 12,235,239 | +26% | Clearline Capital LP | 31 Dec 2025 |
| XPER | Xperi Inc. | Common Stock (par value $0.001 per share) | 6.4% | $17,787,867 | 2,949,895 | Clearline Capital LP | 31 Dec 2025 | ||
| TXMD | TherapeuticsMD, Inc. | Common Stock, par value $0.001 per share | 5.5% | $705,096 | 635,222 | Clearline Capital LP | 31 Dec 2024 | ||
| MX | MAGNACHIP SEMICONDUCTOR Corp | Common Stock, par value $0.01 per share | 4.1% | $3,725,642 | -$1,119,807 | 1,461,036 | -23% | Clearline Capital LP | 31 Dec 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|